Preferred Name |
abciximab |
|
Synonyms |
|
|
ID |
http://www.semanticweb.org/ontologies/STO.owl#OWLClass_8bc22209_b564_4f6f_b14b_4fbbb2731f82 |
|
hasDbXref | ||
isDefinedBy |
Abciximab (ReoPro) is the Fab fragment of a chimeric human/mouse monoclonal antibody directed against the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, the final mediator of aggregation. Abciximab appears to be safe when administered up to 24 hours after stroke onset, and it might improve functional outcome. |
|
label |
abciximab |
|
prefixIRI |
OWLClass_8bc22209_b564_4f6f_b14b_4fbbb2731f82 |
|
prefLabel |
abciximab |
|
references |
Abciximab in Ischemic Stroke Investigators. (2000). Abciximab in Acute Ischemic Stroke A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. Stroke, 31(3), 601-609. |
|
subClassOf |
http://www.semanticweb.org/ontologies/STO.owl#OWLClass_ffc0ae5b_54f3_4a09_ad23_cbc9ad4c3700 http://www.semanticweb.org/ontologies/STO.owl#OWLClass_e719f7b5_d99d_42b0_a34c_a941525d468e |